mortality/aging
• most mice die by P11, although about 19% survive as long as wild-type controls
|
integument
• transepidermal water loss of skin at P7 is approximately 6 times that of controls
• toluidine blue exclusion assay shows that more dye remains in some parts of the skin than in wild-type mice
|
• P5 skin shows infiltration of mainly lymphocytes in the dermis
• treatment with a mAb that selectively neutralizes IL-17A results in decreased inflammatory cell infiltration of the entire dermis
|
• P5 skin shows many keratinous follicular plugs
|
• P5 skin shows severe hyperkeratosis with many follicular plugs and parakeratosis
• treatment with a mAb that selectively neutralizes IL-17A results in tinner epidermis, especially the stratum corneaum
|
• P5 skin shows severe parakeratosis
|
acanthosis
(
J:360877
)
• P5 skin shows severe acanthosis
|
scaly skin
(
J:360877
)
• mice start to show abnormal scaling of the skin over the whole body at postnatal days 4-6
• treatment with a mAb that selectively neutralizes IL-17A results in decreased scales and crusts on ear skin
|
skin lesions
(
J:360877
)
• P5 mice exhibit skin lesions
• mice intraperitoneally injected with a mAb that selectively neutralizes IL-17A show improvement of skin lesions
|
growth/size/body
• weight gain markedly slows after P5
|
homeostasis/metabolism
• transepidermal water loss of skin at P7 is approximately 6 times that of controls
• toluidine blue exclusion assay shows that more dye remains in some parts of the skin than in wild-type mice
|
immune system
• P5 skin shows infiltration of mainly lymphocytes in the dermis
• treatment with a mAb that selectively neutralizes IL-17A results in decreased inflammatory cell infiltration of the entire dermis
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
pityriasis rubra pilaris | DOID:9212 |
OMIM:173200 |
J:360877 |